• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Briggs Morrison - Articles and news items

AstraZeneca

AstraZeneca updates on progress of oncology pipeline at ESMO 2014 congress

Industry news / 29 September 2014 / AstraZeneca

AstraZeneca will present new data from its pipeline of investigational cancer medicines over the next three days at the European Society of Medical Oncology (ESMO) 2014 Congress in Madrid…

AstraZeneca

FDA Advisory Committee votes on accelerated approval for investigational medicine olaparib

Industry news / 26 June 2014 / AstraZeneca

AstraZeneca today announced that the US Food and Drug Administration Oncologic Drugs Advisory Committee voted 11 to 2 that current evidence from clinical studies does not support an accelerated approval for use of olaparib…

AstraZeneca

AstraZeneca to demonstrate the strength and rapid acceleration of its oncology pipeline at ASCO 2014

Industry news / 15 May 2014 / AstraZeneca

New data from AstraZeneca’s investigational cancer medicines demonstrate the rapid progression of its oncology pipeline…

AstraZeneca

Amgen and AstraZeneca announce positive results from Phase III study of brodalumab (AMG 827) in patients with moderate-to-severe plaque psoriasis

Industry news / 12 May 2014 / AstraZeneca

Study evaluating novel investigational IL-17 receptor antibody meets all primary and secondary endpoints…

AstraZeneca

US FDA approves EPANOVA for the treatment of adults with severe hypertriglyceridaemia

Industry news / 6 May 2014 / AstraZeneca

AstraZeneca announced that the US Food and Drug Administration has approved EPANOVA (omega-3-carboxylic acids) as an adjunct to diet to reduce triglyceride levels in adults with severe hypertriglyceridaemia…

AstraZeneca

US FDA approves Bydureon® Pen (exenatide extended-release for injectable suspension) for once-weekly treatment of adults with type 2 diabetes

Industry news / 3 March 2014 / AstraZeneca

AstraZeneca announced that the US Food and Drug Administration has approved the BYDUREON® Pen 2 mg as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes…

AstraZeneca

US FDA approves FARXIGA™ (dapagliflozin) tablets for the treatment of adult patients with type 2 diabetes

Industry news / 13 January 2014 / AstraZeneca

AstraZeneca and Bristol-Myers Squibb Company announced the FDA approved FARXIGA™ (dapagliflozin), a once-daily oral treatment indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus…

AstraZeneca

AstraZeneca announces top-line results from phase III monotherapy study of lesinurad in gout patients

Industry news / 13 December 2013 / AstraZeneca

Lesinurad is an investigational agent being studied as a selective uric acid re-absorption inhibitor that inhibits the URAT1 transporter…

AstraZeneca

ONGLYZA® (saxagliptin) demonstrates no increased risk for cardiovascular death, heart attack or stroke in SAVOR cardiovascular outcomes trial

Industry news, News / 2 September 2013 / AstraZeneca

SAVOR provides information on cardiovascular safety for Onglyza in the wake of past questions about cardiovascular safety of type 2 diabetes treatments…

AstraZeneca

AstraZeneca announces top-line results from Phase III OSKIRA Trials of FOSTAMATINIB

Industry news, News / 4 June 2013 / AstraZeneca

AstraZeneca announced top-line results from OSKIRA-2 and OSKIRA-3…

AstraZeneca
AstraZeneca

AstraZeneca announces results from long-term safety trial of naloxegol in patients with opioid-induced constipation

Industry news, News / 26 February 2013 / AstraZeneca

AstraZeneca announced high-level results from KODIAC-08…

 

Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionWATCH NOW
+ +